TVGN Stock Overview
Operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Tevogen Bio Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.64 |
| 52 Week High | US$21.09 |
| 52 Week Low | US$0.42 |
| Beta | 0.37 |
| 11 Month Change | -10.04% |
| 3 Month Change | -35.68% |
| 1 Year Change | -94.00% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -93.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| TVGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 14.7% | -1.0% | 0.2% |
| 1Y | -94.0% | 9.7% | 17.6% |
Return vs Industry: TVGN underperformed the US Biotechs industry which returned 9.3% over the past year.
Return vs Market: TVGN underperformed the US Market which returned 17.5% over the past year.
Price Volatility
| TVGN volatility | |
|---|---|
| TVGN Average Weekly Movement | 15.5% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: TVGN's share price has been volatile over the past 3 months.
Volatility Over Time: TVGN's weekly volatility has decreased from 27% to 15% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 19 | Ryan Saadi | tevogen.com |
Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer.
Tevogen Bio Holdings Inc. Fundamentals Summary
| TVGN fundamental statistics | |
|---|---|
| Market cap | US$106.84m |
| Earnings (TTM) | -US$19.21m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.6x
P/E RatioIs TVGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TVGN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$19.21m |
| Earnings | -US$19.21m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.12 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -28.5% |
How did TVGN perform over the long term?
See historical performance and comparison